Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2017 1
2018 1
2019 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G. Martin P, et al. Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26. Gut. 2015. PMID: 25429051 Free PMC article.
Following a single administration in mice, TG1050 induced robust, multispecific and long-lasting HBV-specific T cells detectable up to 1 year post-injection. ...These results warrant clinical evaluation of TG1050 in the treatment of CHB....
Following a single administration in mice, TG1050 induced robust, multispecific and long-lasting HBV-specific T cells detectable up t …
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G. Zoulim F, et al. Hum Vaccin Immunother. 2020;16(2):388-399. doi: 10.1080/21645515.2019.1651141. Epub 2019 Oct 4. Hum Vaccin Immunother. 2020. PMID: 31373537 Free PMC article. Clinical Trial.
All doses were well tolerated in both cohorts, without severe adverse event. TG1050 was capable to induce IFN-gamma producing T-cells targeting 1 to 3 encoded antigens, in particular at the 10(10)vp dose. Overall, minor decreases of HBsAg were observed while a number of va …
All doses were well tolerated in both cohorts, without severe adverse event. TG1050 was capable to induce IFN-gamma producing T-cells …
A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.
Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. Kratzer R, et al. Hum Vaccin Immunother. 2018 Jun 3;14(6):1417-1422. doi: 10.1080/21645515.2018.1433970. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29388874 Free PMC article.
HBV-DNA (viremia) and HBsAg levels, were 52% and 51% in TG1050 treated mice, compared with 8% and 22%, respectively, in untreated mice. No significant impact of HBsAg level at baseline on response to TG1050 treatment was found. ...This meta-analysis confirms the the …
HBV-DNA (viremia) and HBsAg levels, were 52% and 51% in TG1050 treated mice, compared with 8% and 22%, respectively, in untreated mic …
Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
Huang D, Sansas B, Jiang JH, Gong QM, Jin GD, Calais V, Yu DM, Zhu MY, Wei D, Zhang DH, Inchauspé G, Zhang XX, Zhu R. Huang D, et al. J Viral Hepat. 2017 Nov;24 Suppl 1:66-74. doi: 10.1111/jvh.12791. J Viral Hepat. 2017. PMID: 29082648
Due to a strong interplay between specific T-cell immunity and elimination of hepatitis B virus (HBV), efforts to develop novel immunotherapeutics are gaining attention. TG1050, a novel immunotherapy, has shown efficacy in an animal study. To support the clinical developme …
Due to a strong interplay between specific T-cell immunity and elimination of hepatitis B virus (HBV), efforts to develop novel immunotherap …
Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?
Yang HC, Kao JH. Yang HC, et al. Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):129-31. doi: 10.1038/nrgastro.2015.8. Epub 2015 Jan 27. Nat Rev Gastroenterol Hepatol. 2015. PMID: 25623202
Martin et al. developed a novel adenovirus-based therapeutic vaccine TG1050 and demonstrated its induction of long-lasting antiviral CD8+ T-cell immunity in mouse models of HBV persistence....
Martin et al. developed a novel adenovirus-based therapeutic vaccine TG1050 and demonstrated its induction of long-lasting antiviral …
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML. Godon O, et al. Vaccine. 2015 Aug 26;33(36):4548-53. doi: 10.1016/j.vaccine.2015.07.020. Epub 2015 Jul 23. Vaccine. 2015. PMID: 26209840
We have developed a novel HBV-targeted immunotherapeutic, TG1050, based on a non-replicative Adenovirus vector encoding a unique and large fusion protein composed of multiple antigenic regions derived from a HBV genotype D sequence. ...This proof-of-concept study supports …
We have developed a novel HBV-targeted immunotherapeutic, TG1050, based on a non-replicative Adenovirus vector encoding a unique and …